ROLE OF MOLECULAR MARKERS IN UNDERSTANDING THE TUMOUR INVASIVENESS OF AMELOBLASTOMA

  • Amol Manoj Karande Oral and Maxillofacial surgeon, Private practitioner, Mumbai- India
  • Rakshit Khandeparkar Oral and Maxillofacial surgeon, Consultant, Apollo victor hospital, Goa-India
  • Cherish Simon Vergeese Periodontist, Private practitioner, Mumbai-India
  • Hunny Jain Oral and Maxillofacial surgeon, Private practitioner, Bhopal-India
Keywords: Ameloblastoma, metastatic invasion, molecular invasion

Abstract

The aim of the present article was to review the current new knowledge on the molecular markers of tumor invasion in ameloblastoma. In this review, tumor molecular markers were identified and allocated to the following six groups according to their functions: (I) Markers involved in extracellular matrix degradation, (II) Molecular markers involved in cell adhesion lost, (III) Molecular markers involved in bone remodeling, (IV) Cytokines involved in angiogenesis, (V) Molecular markers related to the function of tumor stromal cells on the invasion of ameloblastoma, and (VI) Molecular markers involved in cell proliferation related with invasion. In general, the location of markers within the tumor and not their quantitative assessments as such is emphasized. Data showed that the correlation among molecular markers of invasive relevance is still not quite clear. Results on markers of tumor invasion and metastatic potential appeared to be too premature for a statement regarding the instinct invasive nature of ameloblastoma. The unraveling of specific new details concerning these mechanisms, whereby the expression and relationships among the molecules are mediated, may provide an opportunity to afford efficient prevention and develop new treatment therapies.

Downloads

Download data is not yet available.

References

1-Barnes L, Eveson JW, Reichart P, Sidransky D. World health organization classification of tumors. Pathology and genetics head and neck tumors [M]. Lyon: IARC Press; 2005.
2.-Pinheiro JJ, Freitas VM, Moretti AI, Jorge AG, Jaeger RG. Local invasiveness of ameloblastoma. The role played by matrix metalloproteinases and proliferative activity. Histopathology 2004;45:65-72.
3.-Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003;92:827-39.
4.-Zhang B, Huang HZ, Tao Q, Liu XQ, Wei J. Association of matrix metalloproteinase-2 activity with cell proliferation and growth in ameloblastoma. Hua Xi Kou Qiang Yi XueZaZhi 2006;24:7-10.
5-Wang A, Zhang B, Huang H, Zhang L, Zeng D, Tao Q, et al. Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC Cancer 2008;8:182.
6.-Zhang B, Zhang J, Xu ZY, Xie HL. Expression of RECK and matrix metalloproteinase-2 in ameloblastoma.BMC Cancer 2009;9:427.
7.-Zhang B, Zhang J, Huang HZ, Xu ZY, Xie HL. Expression and role of metalloproteinase-2 and endogenous tissue regulator in ameloblastoma. J Oral Pathol Med 2010;3:219-22.
8.-Shen LC, Chen YK, Hsue SS, Shaw SY. Expression of osteonectin/secreted protein acidic and rich in cysteine and matrix metalloproteinases in ameloblastoma. J Oral Pathol Med 2010;39:242-9.
9.-Er N, Dagdeviren A, Tasman F, Zeybek D. Neural cell adhesion molecule and neurothelin expression in human ameloblastoma. J Oral MaxillofacSurg 2001;59:900-3.
10.-Kumamoto H, Ooya K. Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med 2006;35:345-51.
11.-Siar CH, Gunduz M, Sugahara T, Sasaki A, Nakajima M, Naomoto Y, et al. Heparanase gene and protein expression in ameloblastoma: possible role in local
invasion of tumor cells. Oral Oncol 2005;41:542-8.
12.-Leocata P, Villari D, Fazzari C, Lentini M, Fortunato C, Nicòtina PA. Syndecan- 1 and wingless-type protein-1 in human ameloblastomas. J Oral Pathol Med 2007;36:394-9.
13.-Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, Almeida OP, CarrascoDaza D, Garcia-Vazquez F, et al. Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas. Oral Oncol 2008;44:805-11.
14.-Heikinheimo K, Morgan PR, Happonen RP, Stenman G, Virtanen I. Distribution of extracellular matrix proteins in odontogenic tumours and developing teeth. Virchows Arch B Cell PatholInclMolPathol 1991;61:101-9.
15.-Souza Andrade ES, da Costa Miguel MC, Pinto LP, de Souza LB. Ameloblastoma and adenomatoid odontogenic tumor: The role of α2β1, α3β1, and α5β1 integrins in local invasiveness and architectural characteristics. AnnDiagnPathol 2007;11:199-205.
16.-Heikinheimo K, Jee KJ, Niini T, Aalto Y, Happonen RP, Leivo I, et al. Gene Expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. J Dent Res 2002;81:525-30.
17.-González-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, et al. Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med 2010;39:103-9.
18.-Sukarawan W, Simmons D, Suggs C. WNT5A expression in ameloblastoma and its roles in regulating enamel epithelium tumorigenic behaviors. Am J Pathol 2010;176:461-71.
19.-Pripatnanont P, Song Y, Harris M, Meghji S. In situ hybridization and immunocytochemical localisation of osteolytic cytokines and adhesion molecules in ameloblastomas. J Oral Pathol Med 1998;27:496-500.
20.-Wang YP, Liu BY. Expression of osteopontin and its receptors in ameloblastomas. Oral Oncol 2009;45:538-42.
21.-Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin. TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8.
22.-Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-êB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000;156:7617.
23.-Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57: 611-6.
24.-Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in
stromal cells. J Surg Res 2001;100:18-24.
25.-Good CR, O'Keefe RJ, Puzas JE, Schwarz EM, Rosier RN. Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. J SurgOncol 2002;79:174- 9.
26.-Kumamoto H, Ooya K. Expression of arathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear
factor-êB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med 2004;33:46-52.
27.-Lim J, Ahn H, Min S, Hong SD, Lee JI, Hong SP. Oligonucleotide microarray analysis of ameloblastoma. J Oral Pathol Med 2006;35: 278-85.
28.-Feng Y, Zhou YM, Hua CG, Tang XF, He DQ. Expression of Twist in a different subtype of ameloblastomas. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 2009;108: 565-70.
29.-Myoken Y, Myoken Y, Okamoto T, Sato JD, Takada K. Immunohistochemical localization of fibroblast growth factor-1(FGF-1) and FGF-2 in cultured human ameloblastoma epithelial cells and ameloblastoma tissues. J Oral Pathol Med 1995;24:387-92.
30.-Fregnani ER, Sobral LM, Alves FA, Soares FA, Kowalski LP, Coletta RD. The presence of myofibroblasts and expression of matrix metalloproteinase-2 (MMP-2) in ameloblastomas correlate with rupture of the Osseous Cortical. PatholOncol Res 2009;15:231-40.
31.-Iezzi G, Piattelli A, Rubini C, Artese L, Goteri G, Fioroni M, et al. CD10 expression in stromal cells of ameloblastoma variants. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 2008;105:206-9.
32.-Sathi GS, Nagatsuka H, Tamamura R, Fujii M, Gunduz M, Inoue M, et al. Stromal cells promote bone invasion by suppressing bone formation in ameloblastoma. Histopathology 2008;53:458-67.
33.-Iezzi G, Piattelli A, Rubini C, Artese L, Goteri G, Perrotti V, et al. Expression of Transforming Growth Factor β1 in Ameloblastomas. J CraniofacSurg 2008;19: 1618-21.
34.-Zhong M, Liu J, Gong YB, Liu JD, Wang J, Zhang B. Expression of p21WAF1, p27KIP1 and cyclin E in ameloblastoma. Zhonghua Kou Qiang Yi XueZaZhi 2005;40: 306-9.
How to Cite
1.
Amol Manoj Karande, Rakshit Khandeparkar, Cherish Simon Vergeese, Hunny Jain. ROLE OF MOLECULAR MARKERS IN UNDERSTANDING THE TUMOUR INVASIVENESS OF AMELOBLASTOMA. Med. res. chronicles [Internet]. 2017Feb.28 [cited 2021Oct.21];4(01):01-9. Available from: https://medrech.com/index.php/medrech/article/view/210
Section
Original Research Article

Most read articles by the same author(s)